Merck (MRK) is back in focus after reporting positive Phase III results from its personalized mRNA cancer vaccine program ...

Oxford biotech secures $47 million to scale cell-based mRNA manufacturing, with an eye on therapies that require repeated ...

PopVax's PVX-001 is designed to remain stable at 2-8°C for at least nine months and protect against a broad range of covid-19 ...

Last week, RFK Jr. and his minions opened a "vaccine injury clinic" at the NIH. With no budget, structure, or leadership ...

So the stock is attached to a real, maturing franchise. The question is what the mRNA platform is worth, and the honest ...

National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times ...

A new mRNA flu vaccine promises a closer match to circulating flu strains. But dysfunction at federal health agencies is ...

Health Secretary Robert F. Kennedy Jr. announced a department-wide effort Thursday to study and treat possible vaccine ...

A new review synthesizes preclinical and clinical evidence showing that lipid nanoparticle biodistribution, mRNA persistence, ...

Iowa’s vaccine policy is up for debate in the hotly contested governor’s race, with the two candidates on the ballot ...

Some of the latest research frontiers are investigating the idea of “cancer vaccines” and other so-called targeted treatments ...

4 COVID-19 vaccines took a record nine months to develop. The international scientific community coordinated by the Coalition for Epidemic Preparedness Innovations (CEPI), which Singapore is part of, ...